microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients

Molecular Biology Reports

Volumn 43, Issue 4, 2016, Pages 229-240

  Bakkar, Ashraf ^a,b   Alshalalfa, Mohammed ^c   Petersen, Lars F ^a   Abou Ouf, Hatem ^a   Al Mami, Amal ^a   Hegazy, Samar A ^a   Feng, Felix ^e   Alhajj, Reda ^c   Bijian, Krikor ^d   Alaoui Jamali, Moulay A ^d   Bismar, Tarek A ^f,g,h  

^a CALGARY LABORATORY SERVICES   (Canada)

^b OCTOBER UNIVERSITY FOR MODERN SCIENCES AND ARTS MSA   (Egypt)

^c UNIVERSITY OF CALGARY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF MICHIGAN   (United States)

^f Departments of Oncology   (Canada)

^g TOM BAKER CANCER CENTRE   (Canada)

^h Rockyview General Hospital   (Canada)

Author keywords

CXCR axis; ERG gene rearrangements; Invasion; MiR338 3p; Prognosis; Prostate cancer

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; MICRORNA; MICRORNA 338 3P; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; CHEMOKINE RECEPTOR CXCR; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; CXCR7 PROTEIN, HUMAN; MIRN338 MICRORNA, HUMAN;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER LOCALIZATION; CANCER RECURRENCE; CELL INVASION; CELL VIABILITY; COHORT ANALYSIS; CONTROLLED STUDY; CXCL12 GENE; CXCR4 GENE; CXCR7 GENE; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SIGNAL TRANSDUCTION; STABLE EXPRESSION; TUMOR VOLUME; ANIMAL; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; SCID MOUSE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL LINE, TUMOR; CHEMOKINE CXCL12; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICE; MICE, SCID; MICRORNAS; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, CXCR; RECEPTORS, CXCR4;

EID: 84961118181     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-016-3948-4     Document Type: Article

References (53)

1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29. doi:10.3322/caac.21254
2. Fong MK, Hare R, Jarkowski A (2012) A new era for castrate resistant prostate cancer: a treatment review and update. J Oncol Pharm Pract. doi:10.1177/1078155212437599
3. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644–648. doi:10.1126/science.1117679
4. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC et al (2012) The TMPRSS2: ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarker Prev 21(9):1497–1509. doi:10.1158/1055-9965.EPI-12-0042
5. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S et al (2008) The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13(6):519–528. doi:10.1016/j.ccr.2008.04.016
6. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A et al (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41(5):619–624. doi:10.1038/ng.370
7. Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R et al (2011) TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS ONE 6(7):e21650. doi:10.1371/journal.pone.0021650
8. Casey OM, Fang L, Hynes PG, Abou-Kheir WG, Martin PL, Tillman HS et al (2012) TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. PLoS ONE 7(7):e41668. doi:10.1371/journal.pone.0041668
9. Fayyaz S, Farooqi AA (2013) miRNA and TMPRSS2-ERG do not mind their own business in prostate cancer cells. Immunogenetics 65(5):315–332. doi:10.1007/s00251-012-0677-2
10. Wang G, Wang Y, Feng W, Wang X, Yang JY, Zhao Y et al (2008) Transcription factor and microRNA regulation in androgen-dependent and -independent prostate cancer cells. BMC Genomics 9(Suppl 2):S22. doi:10.1186/1471-2164-9-S2-S22
11. Selcuklu SD, Donoghue MT, Spillane C (2009) miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans 37(Pt 4):918–925. doi:10.1042/BST0370918
12. Gordanpour A, Stanimirovic A, Nam RK, Moreno CS, Sherman C, Sugar L et al (2011) miR-221 Is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer. Anticancer Res 31(2):403–410
13. Hart M, Wach S, Nolte E, Szczyrba J, Menon R, Taubert H et al (2013) The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer. FEBS J 280(9):2105–2116. doi:10.1111/febs.12236
14. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297
15. Lai EC (2002) Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 30(4):363–364. doi:10.1038/ng865
16. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1):15–20. doi:10.1016/j.cell.2004.12.035
17. Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K et al (2005) Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature 434(7031):338–345. doi:10.1038/nature03441
18. Chen X, Gong J, Zeng H, Chen N, Huang R, Huang Y et al (2010) MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res 70(7):2728–2738. doi:10.1158/0008-5472.CAN-09-3718
19. Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S (2010) Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol 42(8):1262–1272. doi:10.1016/j.biocel.2009.12.017
20. Dong Q, Meng P, Wang T, Qin W, Qin W, Wang F et al (2010) MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS ONE 5(4):e10147. doi:10.1371/journal.pone.0010147
21. Barik S (2008) An intronic microRNA silences genes that are functionally antagonistic to its host gene. Nucleic Acids Res 36(16):5232–5241. doi:10.1093/nar/gkn513
22. Tomomura M, Fernandez-Gonzales A, Yano R, Yuzaki M (2001) Characterization of the apoptosis-associated tyrosine kinase (AATYK) expressed in the CNS. Oncogene 20(9):1022–1032. doi:10.1038/sj.onc.1204210
23. Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, de Bruijn E et al (2005) MicroRNA expression in zebrafish embryonic development. Science 309(5732):310–311. doi:10.1126/science.1114519
24. Kos A, Olde Loohuis NF, Wieczorek ML, Glennon JC, Martens GJ, Kolk SM et al (2012) A potential regulatory role for intronic microRNA-338-3p for its host gene encoding apoptosis-associated tyrosine kinase. PLoS ONE 7(2):e31022. doi:10.1371/journal.pone.0031022
25. Tsuchiya S, Oku M, Imanaka Y, Kunimoto R, Okuno Y, Terasawa K et al (2009) MicroRNA-338-3p and microRNA-451 contribute to the formation of basolateral polarity in epithelial cells. Nucleic Acids Res 37(11):3821–3827. doi:10.1093/nar/gkp255
26. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K et al (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52(1):145–176
27. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63(6):1256–1272. doi:10.1124/mol.63.6.1256
28. Zlotnik A (2006) Involvement of chemokine receptors in organ-specific metastasis. Contrib Microbiol 13:191–199. doi:10.1159/000092973
29. Begley LA, MacDonald JW, Day ML, Macoska JA (2007) CXCL12 activates a robust transcriptional response in human prostate epithelial cells. J Biol Chem 282(37):26767–26774. doi:10.1074/jbc.M700440200
30. Uygur B, Wu WS (2011) SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis. Mol Cancer 10:139. doi:10.1186/1476-4598-10-139
31. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA et al (2003) Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89(3):462–473. doi:10.1002/jcb.10522
32. Singareddy R, Semaan L, Conley-Lacomb MK, St John J, Powell K, Iyer M et al (2013) Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions. Mol Cancer Res 11(11):1349–1361. doi:10.1158/1541-7786.MCR-12-0705
33. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11–22. doi:10.1016/j.ccr.2010.05.026
34. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ et al (1996) Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2(9):1627–1636
35. Yang JH, Li JH, Jiang S, Zhou H, Qu LH (2013). ChIPBase: a database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data. Nucleic Acids Res 41(Database issue):D177–D187. doi:10.1093/nar/gks1060
36. Guo B, Liu L, Yao J, Ma R, Chang D, Li Z et al (2014) miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a. Mol Cancer Res 12(3):313–321. doi:10.1158/1541-7786.MCR-13-0507
37. Xue Q, Sun K, Deng HJ, Lei ST, Dong JQ, Li GX (2014) MicroRNA-338-3p inhibits colorectal carcinoma cell invasion and migration by targeting smoothened. Jpn J Clin Oncol 44(1):13–21. doi:10.1093/jjco/hyt181
38. Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, Chen LZ et al (2009) Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res 39(8):786–794. doi:10.1111/j.1872-034X.2009.00502.x
39. Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11(9):597–610. doi:10.1038/nrg2843
40. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E et al (2007) A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317(5842):1220–1224. doi:10.1126/science.1140481
41. Walter BA, Valera VA, Pinto PA, Merino MJ (2013) Comprehensive microRNA Profiling of Prostate Cancer. J Cancer 4(5):350–357. doi:10.7150/jca.6394
42. Keeley EC, Mehrad B, Strieter RM (2010) CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res 106:91–111. doi:10.1016/S0065-230X(10)06003-3
43. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I (2007) Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 98(11):1652–1658. doi:10.1111/j.1349-7006.2007.00606.x
44. Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA et al (2009) CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg 137(3):615–621. doi:10.1016/j.jtcvs.2008.07.039
45. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D et al (2004) CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64(23):8604–8612. doi:10.1158/0008-5472.CAN-04-1844
46. Cai J, Kandagatla P, Singareddy R, Kropinski A, Sheng S, Cher ML et al (2010) Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells. Transl Oncol 3(3):195–203
47. Carlisle AJ, Lyttle CA, Carlisle RY, Maris JM (2009) CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation. Mol Cancer 8:126. doi:10.1186/1476-4598-8-126
48. Li X, Ma Q, Xu Q, Liu H, Lei J, Duan W et al (2012) SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Cancer Lett 322(2):169–176. doi:10.1016/j.canlet.2012.02.035
49. Huang XH, Chen JS, Wang Q, Chen XL, Wen L, Chen LZ et al (2011) miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J Pathol 225(3):463–472. doi:10.1002/path.2877
50. Sun K, Deng HJ, Lei ST, Dong JQ, Li GX (2013) miRNA-338-3p suppresses cell growth of human colorectal carcinoma by targeting smoothened. World J Gastroenterol 19(14):2197–2207. doi:10.3748/wjg.v19.i14.2197
51. Ok S, Kim SM, Kim C, Nam D, Shim BS, Kim SH et al (2012) Emodin inhibits invasion and migration of prostate and lung cancer cells by downregulating the expression of chemokine receptor CXCR4. Immunopharmacol Immunotoxicol 34(5):768–778. doi:10.3109/08923973.2012.654494
52. Shanmugam MK, Manu KA, Ong TH, Ramachandran L, Surana R, Bist P et al (2011) Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model. Int J Cancer 129(7):1552–1563. doi:10.1002/ijc.26120
53. Weinberg RA (2014) The Biology of Cancer Garland Science, 2nd edn. Taylor & Francis Group, LLC, New York